Actively Recruiting
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Led by M.D. Anderson Cancer Center · Updated on 2026-02-19
16
Participants Needed
1
Research Sites
459 weeks
Total Duration
On this page
Sponsors
M
M.D. Anderson Cancer Center
Lead Sponsor
N
National Cancer Institute (NCI)
Collaborating Sponsor
AI-Summary
What this Trial Is About
This phase I trial studies the side effects of allogeneic adenovirus-specific cytotoxic T lymphocytes (donor T cell therapy) and to see how well they work in treating patients with a weakened immune system (immunocompromised) and adenovirus-related disease. Allogeneic adenovirus-specific cytotoxic T lymphocytes are made from donated blood cells grown in the laboratory and are designed to kill viruses that can cause infections in immunocompromised patients with adenovirus-related disease.
CONDITIONS
Official Title
Donor T Cell Therapy in Treating Immunocompromised Patients With Adenovirus-Related Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Immunocompromised patients
- Patients 1 year of age or older
- Patients with asymptomatic adenovirus viremia confirmed by two positive qPCR tests one week apart or one measurement with �3e= 1000 copies
- Patients with probable or definitive adenoviral disease
- Women of childbearing potential must have a negative pregnancy test and agree to use effective contraception during the study
- Written informed consent or assent from patient, parent, or guardian
- Willingness to follow study protocol requirements
- English and non-English speaking patients
You will not qualify if you...
- Receiving prednisone > 0.1 mg/kg/day or equivalent at enrollment
- Received anti-thymocyte globulin (ATG) within 14 days before enrollment
- Received donor lymphocyte infusion (DLI) or Campath within 28 days before enrollment
- Having uncontrolled bacterial infections without at least 72 hours of stable therapy
- Having uncontrolled fungal infections without at least 1 week of stable antifungal therapy
- Active acute graft versus host disease (GVHD) grade �3e= 2
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
D
David Marin, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here